Find verified Paliperidone API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Paliperidone for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Paliperidone API.
Alternate Names: 9 Hydroxy risperidone, 9 Hydroxyrisperidone, 9 OH risperidone, 9-hydroxy-risperidone, 9-hydroxyrisperidone, 9-OH-risperidone, Invega, Invega Sustenna, paliperidone, paliperidone palmitate
CAS No: 144598-75-4
PubChem CID: 115237
Mol Formula: C23H27FN4O3
Mol Weight: 426.5 g/mol
IUPAC Name: 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
API Description: Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.
